Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 5.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 110,632 shares of the company’s stock after selling 6,785 shares during the quarter. Rice Hall James & Associates LLC owned about 0.11% of Neurocrine Biosciences worth $15,101,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in NBIX. Creative Planning boosted its holdings in shares of Neurocrine Biosciences by 12.3% during the third quarter. Creative Planning now owns 12,999 shares of the company’s stock worth $1,498,000 after purchasing an additional 1,426 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares during the last quarter. Raymond James & Associates boosted its holdings in shares of Neurocrine Biosciences by 4.3% during the third quarter. Raymond James & Associates now owns 62,446 shares of the company’s stock worth $7,195,000 after purchasing an additional 2,552 shares during the last quarter. Stanley Laman Group Ltd. boosted its holdings in shares of Neurocrine Biosciences by 36.8% during the third quarter. Stanley Laman Group Ltd. now owns 37,531 shares of the company’s stock worth $4,324,000 after purchasing an additional 10,088 shares during the last quarter. Finally, Lecap Asset Management Ltd. boosted its holdings in shares of Neurocrine Biosciences by 42.6% during the third quarter. Lecap Asset Management Ltd. now owns 8,072 shares of the company’s stock worth $930,000 after purchasing an additional 2,412 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on NBIX. HC Wainwright reduced their target price on Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Canaccord Genuity Group reduced their target price on Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft began coverage on Neurocrine Biosciences in a report on Tuesday, February 11th. They issued a “hold” rating and a $138.00 target price on the stock. Bank of America reduced their target price on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, UBS Group lifted their target price on Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $166.90.

Insider Buying and Selling

In related news, CFO Matt Abernethy sold 2,558 shares of Neurocrine Biosciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $116.86, for a total value of $298,927.88. Following the completion of the transaction, the chief financial officer now directly owns 34,775 shares in the company, valued at approximately $4,063,806.50. This trade represents a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $152.92, for a total value of $413,954.44. Following the completion of the transaction, the director now owns 517,030 shares of the company’s stock, valued at $79,064,227.60. This trade represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 236,600 shares of company stock worth $34,348,261. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $115.02 on Tuesday. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The firm has a market cap of $11.65 billion, a price-to-earnings ratio of 34.96 and a beta of 0.33. The stock’s 50-day simple moving average is $137.55 and its 200-day simple moving average is $130.19.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. As a group, research analysts predict that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.